1900 Lake Park Drive
Suite 380
Smyrna, GA 30080
United States
678 384 7220
https://www.geovax.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David Alan Dodd | Chairman, President & CEO | 384.2k | N/A | 1950 |
Dr. Mark J. Newman Ph.D. | Chief Scientific Officer | 291.5k | N/A | 1955 |
Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer | 361.03k | N/A | 1951 |
Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board | N/A | N/A | 1938 |
Mr. Mark W. Reynolds CPA | CFO & Corporate Secretary | 348.2k | N/A | 1962 |
Mr. Thomas O'Brien | Vice President of Quality Systems & Compliance | N/A | N/A | N/A |
Mr. Jeffrey Welch | Head of Process Development & Manufacturing Operations | N/A | N/A | N/A |
Mr. John Niles | Head of Commercial Operations | N/A | N/A | N/A |
Dr. John W. Sharkey Ph.D. | Vice President of Business Development | N/A | N/A | 1956 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
GeoVax Labs, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.